RCC — advances in targeted therapeutics and genomics
Authors:
- 29 December 2016
- journal article
- review article
- Published by Springer Nature in Nature Reviews Urology
- Vol. 14 (2) , 76-78
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after NephrectomyNew England Journal of Medicine, 2016
- Targeting renal cell carcinoma with a HIF-2 antagonistNature, 2016
- On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer modelsNature, 2016
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trialThe Lancet Oncology, 2016
- Comprehensive Molecular Characterization of Papillary Renal-Cell CarcinomaNew England Journal of Medicine, 2016
- Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinomaThe Lancet Oncology, 2016
- The Somatic Genomic Landscape of Chromophobe Renal Cell CarcinomaCancer Cell, 2014
- Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancersNature Reviews Urology, 2014
- Comprehensive molecular characterization of clear cell renal cell carcinomaNature, 2013
- The genetic basis of kidney cancer: a metabolic diseaseNature Reviews Urology, 2010